Revenio Group

13.94 EUR

-1.69 %

14,341 following

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-1.69 %
-14.37 %
-22.73 %
-37.77 %
-37.49 %
-48.75 %
-55.46 %
-77.07 %
+633.68 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
371.93M EUR
Turnover
396.5K EUR
P/E (adj.) (26e)
16.99
EV/EBIT (adj.) (26e)
19.12
P/B (26e)
1.9
EV/S (26e)
3.27
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
20.00 EUR
Updated
29.04.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 29.04.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.8
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Atmosphere from the Annual General Meeting (AGM) First, I must note how satisfied the entire Revenio management, including Demant, is with the upcoming acquisition. During the informal part of the meeting, I spoke with Jouni Toijala (CEO), Arne Boye Nielsen (Chairman), Erkki Tala...
5/12/2026, 6:12 PM
by Pandakarhu
132
By the way, here is one nugget of information from yesterday that I don’t think was in the report or the interview. People here have also been asking why management isn’t buying if it’s such a good deal. The short answer is because the lawyers are saying it’s better if you don’t ...
4/29/2026, 2:53 PM
by Juha Kinnunen
89
I have followed the tightening competition in the optical industry for over 30 years. Stores are being closed, customer service staff is being reduced, there is a constant rush, and set profit targets must be met. I do not believe that they can get anywhere near Revenio’s current...
5/14/2026, 10:02 AM
by Optis
61
Thank you very much for your comprehensive annual general meeting report. As a long-standing ophthalmologist and researcher, I am understandably of a different opinion than optometrist Tala regarding, among other things, the wisdom of purchasing refraction systems and other “optics...
5/13/2026, 12:52 PM
by Optis
49
Inderes Jukka Kainulainen nimitetty Revenion talousjohtajaksi sekä johtoryhmän... Revenio Group Oyj | Pörssitiedote | 13.05.2026 klo 18:30:00 EESTJukka Kainulainen (s. 1982) on nimitetty Revenion talousjohtajaksi ja johtoryhmän jäseneksi, raportoiden toimitusjohtaja Jouni... Jukka...
5/13/2026, 3:40 PM
by Montau
16
Thanks for the answer. I’ve probably been involved for 20+ years myself, dating back to the Done “general store” days. Now it feels like we’re heading back in that direction instead of keeping a sharp focus on eye diagnostics! Simply buying an OCT would have suited me best—ideally...
5/15/2026, 6:17 AM
by Optis
15
I have also been involved for a long time, 20+ years. What would have been Revenio’s alternative? Continue as is, distribute the funds as dividends? Just OCT? By acquiring or developing in-house? Some other way to expand or invest? Perhaps the same margins are no longer available...
5/15/2026, 5:31 AM
by Sissos
14
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.